Assessing patient withdrawal in cancer clinical trials: A systematic evaluation of reasons and transparency in reporting. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

MANCHESTER: Unlike Sunday, it was a bright and sunny morning here at the Old Trafford Cricket Ground on Monday. The surface, which had been under cover due to rain, probably saw the sunlight for the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a ...

A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated ...